Corixa Corp. (Seattle, WA) and Glaxosmithkline (GSK) (Philadelphia, PA) received FDA approval for Bexxar (tositumomab & iodine-131 tositumomab) for treating patients with rituximab-refractory, CD20-positive, follicular non-Hodgkin's lymphoma (NHL) with and without transformation. The companies will co-promote the product in the U.S. and will be ready to start filling orders by about the end of July. This milestone was hard won by the companies. The way to approval was cleared in December when an FDA advisory panel decided that the data on Bexxar supported its efficacy in NHL, overturning the agency's March 2002 decision to reject the product.
展开▼
